470 related articles for article (PubMed ID: 31419963)
1. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study.
Kuo YH; Lai CH; Huang CY; Chen CJ; Huang YC; Huang WS; Chin CC
BMC Cancer; 2019 Aug; 19(1):815. PubMed ID: 31419963
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
Akasu T; Moriya Y; Ohashi Y; Yoshida S; Shirao K; Kodaira S;
Jpn J Clin Oncol; 2006 Apr; 36(4):237-44. PubMed ID: 16675478
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study.
Uzcudun AE; Batlle JF; Velasco JC; Sánchez Santos ME; Carpeño Jde C; Grande AG; Juberías AM; Piñeiro EH; Olivar LM; García AG
Dis Colon Rectum; 2002 Oct; 45(10):1349-58. PubMed ID: 12394434
[TBL] [Abstract][Full Text] [Related]
4. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
7. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
8. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY
PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
10. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
Thomschke D; Kyau-Ummen B; Halbfass HJ
Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
[TBL] [Abstract][Full Text] [Related]
11. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
Oki E; Kakeji Y; Yoshida R; Ikeda K; Nishida K; Koga T; Egashira A; Tokunaga E; Morita M; Baba H; Maehara Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():138-43. PubMed ID: 16897990
[TBL] [Abstract][Full Text] [Related]
12. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
[TBL] [Abstract][Full Text] [Related]
13. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Bonnen M; Crane C; Vauthey JN; Skibber J; Delclos ME; Rodriguez-Bigas M; Hoff PM; Lin E; Eng C; Wong A; Janjan NA; Feig BW
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1098-105. PubMed ID: 15519780
[TBL] [Abstract][Full Text] [Related]
14. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
[TBL] [Abstract][Full Text] [Related]
16. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
[TBL] [Abstract][Full Text] [Related]
18. Rectal cancer adjuvant chemotherapy: when is more useful?
Pasetto LM; Basso U; Sinigaglia G; Pucciarelli S; Friso ML; Rugge M; Toppan P; Agostini M; Monfardini S
Anticancer Res; 2008; 28(3B):1805-12. PubMed ID: 18630464
[TBL] [Abstract][Full Text] [Related]
19. Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
Huh JW; Kim HR
J Surg Oncol; 2009 Oct; 100(5):387-91. PubMed ID: 19582821
[TBL] [Abstract][Full Text] [Related]
20. Pathologic Staging Inconsistency Between ypT4N0 (stage II) and ypT1-2N1 (stage III) After Preoperative Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer: A Multi-Institutional Study.
Lee JH; Yu M; Kim SH; Lee JH; Sung SY; Jeong BK; Jeong S; Nam TK; Jeong JU; Jang HS
Clin Colorectal Cancer; 2019 Mar; 18(1):e130-e139. PubMed ID: 30595556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]